MedTrace Logo

Decatecholaminisation of Septic Shock With Dexmedetomidine and In-hospital Mortality

NCT05283083 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2023-05-06

No results posted yet for this study

Summary

The study aims to determine whether the infusion of DEX in septic shock can reduce in-hospital mortality, norepinephrine infusion, need and duration for mechanical ventilation, and acute kidney injury without significant adverse events.

Conditions

Interventions

DRUG

Dexmedetomidine

A highly-selective alpha-2 agonist with sedative, analgesic, and sympatholytic effects.

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • Moataz M Emara, MD, EDAIC · Mansoura University Faculty of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-25
Primary Completion
2023-02-01
Completion
2023-03-01
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05283083 on ClinicalTrials.gov